Guatemala - İspanyolca - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

schwabe north america inc. - cápsulas

Peru - İspanyolca - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

sebal farma distribuciones s.a.c. -

Peru - İspanyolca - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

siemens healthcare s.a.c. -

Peru - İspanyolca - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

inmunochem s.a.c. -

Guatemala - İspanyolca - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

schwabe north america inc. - cápsula blanda

Peru - İspanyolca - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

inversiones y distribuidora verdi s.a.c. - droguerÍa - capsula blanda - por capsula - - multivitamínicos con hierro

Guatemala - İspanyolca - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

novutech llc - cápsulas

Avrupa Birliği - İspanyolca - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Avrupa Birliği - İspanyolca - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals para leporidae - conejos - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Avrupa Birliği - İspanyolca - EMA (European Medicines Agency)

instituto grifols s.a. - la inmunoglobulina humana normal - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - los sueros inmunes e inmunoglobulinas, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.